Mitsubishi Tanabe Pharma Corporation

Shanghai Pharmaceuticals Holding Co., Ltd.

Astrazeneca Ab

Hiroshi Sugama

Jingkang Shen

Toru Iijima

Guangxin Xia

Takayuki Kawaguchi

Jianshu Xie

Miki Hirai

Kazutoshi Sugawara

Tetsuji Matsudaira

Yoichi Takahashi

Masao Nawano

Rikiya Ohashi

Giulia Bergonzini

Henrik Gradén

Takehiko Matsumura

Hidenori Akatsuka

Iwao Takamuro

Lars Anders Mikael Johansson

Nobumasa Awai

Huixin Wan

Yuko Togashi

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R, R, R, R, R, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

Compounds and their use

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein Ris a cycloalkyl group and the like, Ris an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is &#x2014;O&#x2014; and the like, and Rto Rare the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.

Nitrogen-containing saturated heterocyclic compound

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein Ris a cycloalkyl group or an alkyl,

Renin inhibitor

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein Ris a cycloalkyl group and the like, Ris an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is &#x2014;O&#x2014; and the like, and Rto Rare the same or different and a hydrogen atom and the like;or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.

The present invention provides a morpholine derivative of the formula [I]; wherein Ris a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; Ris a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R, R, Rand Rare the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group;or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.

Morpholine derivative

A hydrazone derivative of formula [I]: wherein Ring A is aryl or heteroaryl, Ring T is heteroaryl or heterocycle, Rand Rare independently hydrogen atom, halogen atom, cycloalkylsulfonyl, etc., Rand Rcombine each other together with the adjacent nitrogen atom to form substituted or unsubstituted heterocycle, Ris hydrogen atom, halogen atom, cyano, nitro, tetrazolyl, etc., and Ris hydrogen atom, etc.;or a pharmaceutically acceptable salt thereof is useful as a glucokinase activation agent.

Hydrazone derivative

The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl;

Oxime derivative and preparations thereof

Growing community of inventors

Osaka, Japan

Hiroshi Sugama